LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Specific Gene Expression Differentiates Moles from Melanoma

By LabMedica International staff writers
Posted on 08 Dec 2016
Image: p15 expressed in nevi is a key factor mediating BRAF-induced growth arrest. A, p15 expression in a benign intradermal nevus and B, antibody control C, co-immunofluorescence of p15 and Melan-A in a representative intradermal benign nevus. D, nevus melanocytes express p15, whereas non- nevus melanocytes (white arrows) are p15-negative (Photo courtesy of University of Pennsylvania).
Image: p15 expressed in nevi is a key factor mediating BRAF-induced growth arrest. A, p15 expression in a benign intradermal nevus and B, antibody control C, co-immunofluorescence of p15 and Melan-A in a representative intradermal benign nevus. D, nevus melanocytes express p15, whereas non- nevus melanocytes (white arrows) are p15-negative (Photo courtesy of University of Pennsylvania).
Most melanomas are driven by mutations that spur out-of-control cell replication, while nevi which are moles composed of non-cancerous cells at the skin surface, that harbor the same mutations do not grow wildly.

Dermatologists surmise that 30% to 40% of melanomas, approximately 30,000 cases per year, may arise in association with a nevus. However, clinicians would like to be able to better distinguish between the two, especially in borderline cases when they examine skin tissue after a patient biopsy.

Scientists at the University of Pennsylvania (Philadelphia, PN, USA) stained human nevus and melanoma tissue samples with p15 and p16 antibodies. Staining was evaluated and graded for percentage and intensity to determine an “H score,” which correlates with the level of protein in the cells. This approach could also form the basis of a clinical determination, taking the form of an antibody test for p15 from a patient’s biopsy specimen. Ribonucleic acid (RNA) was also extracted from 14 nevus and melanoma tissue samples to determine levels of p15 messenger RNA (mRNA). The expression of p15 mRNA was significantly increased in melanocytic nevi compared with melanomas as determined by real-time quantitative real-time quantitative polymerase chain reaction (RT-PCR) analysis.

John T. Seykora, MD, PhD, a professor of Dermatology and senior author of the study, said, “We showed that p15 expression is a robust biomarker for distinguishing nevus from melanoma. Making this distinction has been a long-standing issue for dermatologists. We hope that this new finding will help doctors determine if a nevus has transformed to melanoma. This could help doctors and patients in difficult cases. If the staining level is high then that would be most consistent with a benign nevus. If the staining level is low then that would be consistent with a melanoma.” The study was published in the December 2016 issue of the American Journal of Pathology.

Related Links:
University of Pennsylvania

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Hemodynamic System Monitor
OptoMonitor

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more